AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2024
Jan 17, 2024
65314_rns_2024-01-17_6d4ec5d2-83ef-4cd5-b973-b87fb7c9e7b9.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX Release 18 January 2024
==> picture [152 x 42] intentionally omitted <==
ASX Code: MEM
Entitlement Offer Prospectus Completion
Pursuant to the pro-rata non-renounceable Entitlement Offer Prospectus dated 4 December 2023 and lodged with ASIC and ASX on same day, the following securities have been allotted today:
Shares issued to applicants: 54,305,732 Shortfall allotment: 158,922,042 Total allotment of shares: 213,227,774 Total shares on issue after allotment: 1,343,858,732
For further information please contact:
ENDS
For further information, please contact:
Dr David Ali Andrew Metcalfe Interim Managing Director / Chief Executive Officer Company Secretary Memphasys Limited Memphasys Limited Tel: +61 2 8415 7300 Tel: +61 412 125 090 E: [email protected]> E: [email protected]
About Memphasys
Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.
Website : www.memphasys.com
The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.